Brind.
  1. Pfizer is developing the drug berobenatide for future growth, referencing its 2023 acquisition of Seagen.

Blackstone has agreed to co-fund the development costs of Pfizer's drug berobenatide.

1 report, 1 independent Updated Wed 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Blackstone has agreed to co-fund the development costs of Pfizer's drug berobenatide.

Who's involved

What this event is mainly about
PfizerBlackstone

Keep exploring

Part of

Pfizer is developing the drug berobenatide for future growth, referencing its 2023 acquisition of Seagen. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped